Mitragyna Speciosa

Mitragyna speciosa contains a diverse group of indole and oxindole alkaloids identified through analytical chemistry research. Studies have characterised at least 19 specific alkaloids, with additional research identifying a broader alkaloid count across plant material and commercial products. The following compounds represent important examples within the documented chemical profile.

• Mitragynine: Mitragynine is a principal indole alkaloid identified in Mitragyna speciosa leaves. Research has examined its chemical structure, metabolism, receptor activity, and concentration across different plant materials.
• Speciociliatine: Speciociliatine is an indole alkaloid structurally related to mitragynine. Chemical studies identify speciociliatine among the principal characterised alkaloids found within the species.
• Speciogynine: Speciogynine is an indole alkaloid identified alongside mitragynine and speciociliatine. Its presence contributes to the broader alkaloid profile of Mitragyna speciosa.
• Mitraciliatine: Mitraciliatine is a structurally related indole alkaloid identified through analytical characterisation. Research places the compound among the documented alkaloids present in Mitragyna speciosa material.
• Paynantheine: Paynantheine is an indole alkaloid identified within the species. Chemical research distinguishes paynantheine from related alkaloids through spectroscopic analysis and structural characterisation.
• Oxindole alkaloids: Oxindole compounds form another part of the documented chemical profile. Research has identified compounds including speciofoline, corynoxine A, corynoxine B, and related structures.

Mitragynine affects the body by interacting with biological systems after absorption and undergoes extensive metabolism within the body. Laboratory and pharmacological research identifies activity involving several receptor systems, including opioid receptors, alongside other signalling pathways. Human metabolism studies identify cytochrome P450 enzymes, particularly CYP3A4, as important contributors to mitragynine metabolism. The resulting metabolites differ chemically from the original compound and contribute to the overall pharmacological profile. Effects depend on factors including product composition, exposure, individual metabolism, and interactions with other substances. Research does not support treating mitragynine as a standard pharmaceutical ingredient.

Traditional uses of Mitragyna speciosa developed across Southeast Asian communities where the species grows naturally. Historical sources describe preparation of fresh leaves, dried leaves, teas, and other botanical forms. Documented practices differ between countries and communities, reflecting local traditions and cultural contexts. Historical use provides evidence of longstanding human interaction with the plant rather than proof of modern clinical effectiveness. Traditional applications described in historical literature include the following categories.

• Leaf chewing: Fresh leaves have historically been chewed within communities in parts of Southeast Asia. Preparation practices differed according to local customs and available plant material.
• Leaf beverages: Leaves have been prepared as teas or other liquid beverages in traditional settings. Preparation methods varied according to regional practices and household preferences.
• Work-related traditions: Historical accounts describe leaf use among workers in tropical environments. Accounts associate the practice with local occupational traditions and cultural routines.
• Community practices: Mitragyna speciosa formed part of traditional botanical knowledge in several Southeast Asian communities. Practices differed according to region, culture, and historical period.

Mitragyna speciosa is a botanical species rather than a pharmaceutical drug assigned to a single FDA drug class. The plant belongs to the Rubiaceae family and contains numerous naturally occurring alkaloids, including mitragynine and related compounds. Pharmacological research examines some of those alkaloids according to receptor activity and metabolic pathways. A botanical classification differs from a regulatory drug classification. United States regulatory treatment depends on the specific product, ingredient, intended use, and applicable federal or state requirements. Product labels and regulatory notices provide the relevant framework for commercial products rather than assigning the plant itself a conventional pharmaceutical class.

Yes, however, the legal status of Mitragyna speciosa varies according to jurisdiction, product composition, and applicable regulations. United States federal controlled substance status differs from FDA treatment of products marketed as dietary supplements or dietary ingredients. FDA issued an August 2026 import alert concerning dietary supplements and bulk dietary ingredients containing Mitragyna speciosa. State and local rules differ, with some jurisdictions imposing specific restrictions or prohibitions. Products containing concentrated individual alkaloids can face separate regulatory considerations from unprocessed botanical material. Legal status requires checking the rules applicable to the specific location and product.

Yes, Mitragyna speciosa is available through online botanical retailers in jurisdictions where sale and possession comply with applicable rules. Online listings commonly include powder, capsules, extracts, liquids, and other prepared forms. Product pages provide varying levels of information regarding botanical source, package size, ingredient composition, and laboratory testing. Availability differs by location because state, national, and local regulations do not follow one universal framework. Online buyers need to review current product information and local requirements before placing an order.